Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Joe Camel "supplements" his portfolio

This article was originally published in The Tan Sheet

Executive Summary

RJ Reynolds Tobacco Company's Avoca division and Next Pharmaceuticals have partnered to develop proprietary dietary supplement ingredients, the firms announce March 8. Flagship Nextracts include the COX-2 anti-inflammatory Nexprofen and Relora, a phenolic complex for anxiety and stress. Others are Standardized Echinacea Purpurea Nextract with 4% phenolic compounds and four Standardized Saw Palmetto Nextracts containing 10%, 25%, 30% and 40% total fatty acids, respectively. The January agreement follows 18 months of R&D; the agricultural and extraction facilities are located at Avoca's 2,400-acre North Carolina facility. Next is courting large pharmaceutical and supplement companies as part of the ingredients' "roll-out" phase

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel